ASSOCIATION OF HYPERTENSION WITH ALL-CAUSE MORTALITY AMONG HOSPITALIZED PATIENTS WITH COVID-19
Enrique Rodilla, Alberto Saura, Iratxe Jiménez, Andrea Mendizábal, Araceli Pineda-Cantedo, Elizabeth Lorenzo-Hernández, Maria Del Pilar Fidalgo-Montero, Joaquín Fernández López-Cuervo, Ricardo Gil-Sánchez, Elisa Rabadán-Pejenaute, Lucy Abella-Vázquez, V. Giner, Marta Nataya Solís Marquínez, Ramón Boixeda, Andrés de la Peña-Fernández, Francisco Javier Carrasco-Sánchez, Julio González Moraleja, José D. Torres‐Peña, María Esther Guisado Espartero, Joaquín Escobar-Sevilla, Marcos Guzmán-García, María Dolores Martín Escalante, Ángel L. Martínez-González, José Manuel Casas Rojo, Ricardo Gómez‐Huelgas
Abstract
Objective: It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. The main objective of the study is to analyze whether HT represents an independent risk factor for death as a hard endpoint in patients hospitalized with SARS-CoV-2 in Spain. Design and method: Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. Results: The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). Conclusions: The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.